Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Hemogenyx happy with progress and recent collaborations

The biotech, which listed in October, is developing two therapies to improve the chances of survival of people requiring a bone marrow transplant
picture of blood in phials
Hemogenyx is working on two therapies

HemoGenyx Pharmaceuticals PLC (LON:HEMO) is making good progress in the laboratory on its two pioneering new treatments for blood cancer sufferers, it told shareholders at its annual meeting.

The biotech, which listed in October, is developing two therapies to improve the chances of survival of people requiring a bone marrow transplant.

READ: Hemogenyx aims for revolution in blood cancer treatment

CDX (a novel bispecific antibody) is an alternative to the current chemotherapy and radiotherapy required in the pre-transplant stage.

HuPHEC (a new cell therapy), meanwhile, aims to improve the way in which bone marrow/hematopoietic stem cell transplants are performed and the treatment’s effectiveness.

Hemogenyx recently appointed LakePharma, the largest US-based biologics contract research organisation, to help speed up the CDX programme.

LakePharma brings the necessary integrated antibody engineering and bioproduction expertise for the preclinical development stages.

A Phase I trial is scheduled for 16 months.

WATCH: Hemogenyx Pharmaceuticals to revolutionise bone marrow transplants

The collaboration with the University of Oxford, meanwhile, if stimulating transplanted blood stem cells can produce healthy cells faster.

This work could lead to additional uses of the company's HuPHEC product and significantly improve the efficiency and safety of future bone marrow transplants.

Vladislav Sandler, Hemogenyx’s chief executive, said: “The appointment of LakePharma and collaboration with Oxford University represent significant steps towards our strategic goal of applying novel technologies to transform the lives of bone marrow transplant patients.“

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Related Articles

cannabis plant
February 01 2018
Today, the group closed the US$18mln acquisition of Citiva Medical and Citiva USA
September 28 2018
HemoGenyx said it was pleased with the opportunities that had been unlocked for its CDX antibodies during the first half

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use